OpaxioTreatment for Non-Small Cell Lung Cancer, Ovarian Cancer, Glioblastoma Multiforme, Head and Neck Cancer
Lung Cancer Alliance Hails FDA Decision to Expedite Review of Xyotax Treatment for Lung Cancer
Drug Holds Hope for Women With First-Line, Advanced Non-small Cell Lung Cancer
WASHINGTON, April 16, 2007 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance hailed the recent decision by the U.S. Food and Drug Administration (FDA) to expedite the review of Xyotax, a cancer drug under development by Cell Therapeutics, Inc., as an exciting and hopeful development for the lung cancer community.
Xyotax is designed to treat certain women with first-line, advanced non- small cell lung cancer.
"For many months we have been carefully watching the progress of Xyotax in clinical trial," said Laurie Fenton Ambrose, President of Lung Cancer Alliance. "If successful, this first-ever, gender-based study could provide significant breakthroughs for women with advanced non-small cell lung cancer."
On April 11, 2007, the FDA reported it would expedite review of the drug because it has shown promising results in treating a life-threatening condition and demonstrates the potential to address an unmet medical need.
"Clearly, there is more testing to do before we can fully evaluate the efficacy of Xyotax for our stakeholders -- but the FDA decision puts us one step further on the path towards discovery," concluded Fenton.
Lung Cancer Alliance is the only national organization providing patient support and advocacy exclusively to those living with or at risk for lung cancer. For more information please visit http://www.lungcanceralliance.org.
CONTACT: Kay Cofrancesco of Lung Cancer Alliance, Office: +1-202-463-2080,Cell: +1-202-744-1541, email@example.com
Web site: http://www.lungcanceralliance.org/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2007
- Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer - January 28, 2014
- High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO Phase II Study Reported in American Journal of Clinical Oncology - February 24, 2011
- Paclitaxel Poliglumex (OPAXIO) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer - November 22, 2010
- OPAXIO Phase II Study Results Confirm High Rate of Complete Response with Low Rate of Side Effects in Patients with Advanced Esophageal Cancer - June 7, 2010
- OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer - October 3, 2009
- Opaxio Combined with Alimta Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer - August 6, 2009
- Paclitaxel Poliglumex (OPAXIO Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer - June 5, 2009
- Paclitaxel Poliglumex (Opaxio)/Capecitabine Regimen Well Toleratedand Active in Metastatic Breast Cancer - June 3, 2008
- CTI and FDA Agree on NDA Filing Strategy for Xyotax - June 1, 2006
- CTI Plans to Submit Marketing Applications for Xyotax - August 24, 2005